



# Daun02

**Catalog No: tcsc0464** 

	_
J	

### **Available Sizes**

Size: 2mg

Size: 5mg

Size: 10mg



## **Specifications**

#### CAS No:

290304-24-4

#### Formula:

 $C_{41}H_{44}N_2O_{20}$ 

### **Pathway:**

Cell Cycle/DNA Damage; Antibody-drug Conjugate/ADC Related

### **Target:**

Topoisomerase; ADC Cytotoxin

#### **Purity / Grade:**

>98%

### **Solubility:**

10 mM in DMSO

### **Observed Molecular Weight:**

884.79

## **Product Description**

Daun02 is converted by  $\beta$ -galactosidase to Daunorubicin, which is a topoisomerase inhibitor.

IC50 & Target: Topoisomerase<sup>[1][2]</sup>

In Vitro:





Daun02 is a prodrug, which is converted by  $\beta$ -galactosidase to Daunorubicin, which has been shown to reduce calcium ion (Ca<sup>2+</sup>)-dependent action potentials in neuroblastoma cells<sup>[1]</sup>. Daunorubicin is a topoisomerase inhibitor<sup>[2]</sup>. Daun02 is a good substrate for  $\beta$ -galactosidase ( $\beta$ -gal). The concentration of Daun02 producing 50% (EC<sub>50</sub>) decrease in cell viability is 0.5  $\mu$ M, 1.5  $\mu$ M, and 3.5  $\mu$ M for T47-D, Panc02, and MCF-7, respectively<sup>[3]</sup>.

In Vivo: Daun02 is a good substrate for  $\beta$ -gal with  $K_m$  and  $V_{max}$  values of 0.37 mM and 8.6  $\mu$ mol/min/mg protein. At a concentration of  $10^{-5}$  M, Daun02 is 79% bound to plasma protein compares to 94% for Daunomycin<sup>[3]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!